Analyst Coverage

Firm Analyst
Cantor Fitzgerald
Kristen Kluska
Guggenheim
Yatin Suneja
H.C. Wainwright & Co.
Joseph Pantginis
Jefferies
Chris Howerton
LifeSci Capital
Sam Slutsky
SVB Leerink
Thomas Smith

Celldex Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Celldex Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Celldex Therapeutics or its management. Celldex Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline